ArticleFrontiers in oncology2026
SCART sequential lattice spatial fractionated radiotherapy combined with chemotherapy for recurrent ovarian cancer with bulky bone metastasis: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stereotactic centralized ablative radiation therapy: a framework for ultra-heterogeneous radiotherapy of bulky tumors.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone metastasis from ovarian cancer is relatively rare, and the treatment of giant bone metastatic lesions poses significant clinical challenges. SCART (Stereotactic Centralized Ablative Radiation Therapy) and Lattice technique, as emerging spatial fractionated precision radiotherapy technologies, have shown unique advantages in treating bulky tumor lesions. This case report explores the potential immunomodulatory effects of spatial fractionated radiotherapy in enhancing tumor antigenicity and chemotherapy sensitivity in recurrent, drug-resistant, multi-line treated cancer patients. Case presentation: We report a 56-year-old female patient with ovarian cancer recurrence and multiple metastases 7 years post-surgery. CT examination revealed a big right iliac bone metastatic lesion (89×78×58mm) with surrounding soft tissue invasion. After limited response to chemotherapy and bevacizumab, the patient underwent sequential SCART, SBRT, and Lattice radiotherapy for her right iliac and surrounding invasive soft tissue metastases. Substantial local tumor regression was achieved without severe acute toxicity. Methods: The initial radiotherapy consisted of SCART followed by SBRT: STV 54 Gy/3 fractions, PGTV 15 Gy/3 fractions, then SBRT PGTV 25 Gy/5 fractions. Stage II treatment used Lattice radiotherapy: VTV 45 Gy/3 fractions and PGTV 9 Gy/3 fractions. Results: The patient's pain symptoms were significantly relieved, with good tolerance during treatment and no severe adverse reactions. According to RECIST 1.1 evaluation criteria, the baseline GTV was 399.0cc, decreased to 308.0cc after SCART +SBRT, and further reduced to 136.1cc at 6-month follow-up MRI after Lattice radiotherapy. The diameter decreased by approximately 30.1% compared to baseline, achieving partial response. Conclusion: The combination of SCART and Lattice techniques offers a promising strategy for managing bulky tumor, particularly suitable for cases with less-responsive to conventional therapy. This technique ensures safe dose at target margins while increasing dose to "cold tumor" areas, offering new clinical options. This approach safely escalates intratumoral dose while protecting normal tissue and may enhance immunogenic and cytotoxic responses. Sequential spatial fractionation techniques appear feasible, with controllable short-term safety and favorable tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.